Cortical Dynamics’ agreement with Philips bodes well for BPH
Diversified ASX-listed group, BPH Energy (ASX:BPH) announced on Friday morning that one of its investee companies (16%), Cortical Dynamics had entered into a non-exclusive Licence and Co-operation Agreement with Philips Healthcare North America Corp.
The agreement will enable Cortical to interface its Brain Anaesthesia Response Monitor (BARM) into the Philips IntelliVue and Patient Information Center (PIC iX) Monitoring Systems using the IntelliBridge integration product line.
Royal Philips (NYSE:PHG, AEX:PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care.
Cortical is an Australian based medical device technology company that has developed a next-generation Brain Function Monitor.
The core-product, the Brain Anaesthesia Response (BAR) monitor, has been developed with the objective of better detecting the effect of anaesthetic agents on brain activity, aiding anaesthetists in keeping patients optimally anaesthetised.
Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.
Philips generated 2019 sales of EUR19.5 billion and employs approximately 81,000 employees across more than 100 countries.
Consequently, this is an important transaction for the group and perhaps an anticipated one given that BPH’s shares doubled yesterday after being up 200% earlier in the session.
Latest articles on BPH Energy
More Commentary
FYI establishes ties with independent ESG reporting platform
01-07-2021
Australian Government Awards FYI National Project Status
29-06-2021
AHI and Nexus-Vita to fast track integration
22-06-2021
Oneview signs long-term contract with a second Victorian hospital
18-06-2021S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.
